1
|
Bernard-Tessier A, Cancel M, Tombal B, Roubaud G, Carles Galceran J, Flechon A, McDermott R, Supiot S, Berthold D, Philippe R, Kacso G, Gravis Mescam G, Calabrò F, Berdah J, Hasbini A, Ricci F, Hennequin C, Ribault H, Foulon S, Fizazi K. 1421P Effect of abiraterone-prednisone in metastatic castration-sensitive prostate cancer (mCSPC) with neuroendocrine and very high-risk features in the PEACE-1 trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
2
|
Colomba E, Jonas S, Eymard JC, Delva R, Brachet P, Neuzillet Y, Penel N, Roubaud G, Bompas E, Mahammedi H, Longo R, Helissey C, Barthelemy P, Borchiellini D, Hasbini A, Priou F, Saldana C, Voog E, Foulon S, Fizazi K. 603P Objective computerized cognitive assessment in men with metastatic castrate-resistant prostate cancer (mCRPC) randomly receiving darolutamide or enzalutamide in the ODENZA trial. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
3
|
Blanchard P, Foulon S, Artignan X, Carles J, Ronchin P, Gizzi M, Villa Freixa S, Valdagni R, Sargos P, Marques Da Costa L, Duberge T, Guillot A, Latorzeff I, Gallardo E, Sáez M, Abadie-Lacourtoisie S, Bennamoun M, Hasbini A, Tantot F, Fizazi K. 646TiP A randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse: The PEACE 2 trial from Unicancer. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
4
|
Le Cesne A, Blay JY, Cupissol D, Italiano A, Delcambre C, Penel N, Isambert N, Chevreau C, Bompas E, Bertucci F, Chaigneau L, Piperno-Neumann S, Salas S, Rios M, Guillemet C, Bay JO, Ray-Coquard I, Haddag L, Bonastre J, Kapso R, Fraslin A, Bouvet N, Mir O, Foulon S. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Ann Oncol 2021; 32:1034-1044. [PMID: 33932507 DOI: 10.1016/j.annonc.2021.04.014] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2021] [Revised: 04/20/2021] [Accepted: 04/22/2021] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND The French Sarcoma Group assessed the efficacy, safety, and quality of life (QoL) of trabectedin versus best supportive care (BSC) in patients with advanced soft tissue sarcoma (STS). PATIENTS AND METHODS This randomized, multicenter, open-label, phase III study included adults with STS who progressed after 1-3 prior treatment lines. Patients were randomized (1 : 1) to receive trabectedin 1.5 mg/m2 every 3 weeks or BSC, stratified into L-STS (liposarcoma/leiomyosarcoma) and non-L-STS groups (other histotypes). Patients from the BSC arm were allowed to cross over to trabectedin at progression. The primary efficacy endpoint was progression-free survival (PFS) confirmed by blinded central review and analyzed in the intention-to-treat population. RESULTS Between 26 January 2015 and 5 November 2015, 103 heavily pre-treated patients (60.2% with L-STS) from 16 French centers were allocated to receive trabectedin (n = 52) or BSC (n = 51). Median PFS was 3.1 months [95% confidence interval (CI) 1.8-5.9 months] in the trabectedin arm versus 1.5 months (0.9-2.6 months) in the BSC arm (hazard ratio = 0.39, 95% CI 0.24-0.64, P < 0.001) with benefits observed across almost all analyzed subgroups, but particularly in patients with L-STS (5.1 versus 1.4 months, P = 0.0001). Seven patients (13.7%) in the trabectedin arm (all with L-STS) achieved a partial response, while no objective responses were observed in the BSC arm (P = 0.004). The most common grade 3/4 adverse events were neutropenia (44.2% of patients), leukopenia (34.6%), and transaminase increase (32.7%). Health-related 30-item core European Organization for the Research and Treatment of Cancer Quality-of-Life Questionnaire evidenced no statistical differences between the arms for any domain and at any time point. After progression, 91.8% of patients crossed over from BSC to trabectedin. CONCLUSION Trabectedin demonstrates superior disease control to BSC without impairing QoL in patients with recurrent STS of multiple histologies, with greater impact in patients with L-STS.
Collapse
Affiliation(s)
- A Le Cesne
- Medical Oncology Department, Gustave Roussy, Villejuif, France.
| | - J-Y Blay
- Medical Oncology Department, Centre Léon Bérard and Claude Bernard University, Lyon, France
| | - D Cupissol
- Medical Oncology Department, Centre Val d'Aurelle, Montpellier, France
| | - A Italiano
- Medical Oncology Department, Institut Bergonié, Bordeaux, France
| | - C Delcambre
- Medical Oncology Department, Centre François Baclesse, Caen, France
| | - N Penel
- Medical Oncology Department, Centre Oscar Lambret and Lille University, Lille, France
| | - N Isambert
- Medical Oncology Department, Centre Georges-François Leclerc, Dijon, France
| | - C Chevreau
- Medical Oncology Department, Institut Claudius Regaud, Toulouse, France
| | - E Bompas
- Medical Oncology Department, Centre René Gauduchau, Nantes, France
| | - F Bertucci
- Medical Oncology Department, Institut Paoli-Calmettes, Marseille, France
| | - L Chaigneau
- Medical Oncology Department, Hôpital Jean Minjoz, Besancon, France
| | | | - S Salas
- Medical Oncology Department, Hôpital La Timone, Marseille, France
| | - M Rios
- Medical Oncology Department, Institut de Cancerologie de Lorraine, Nancy, France
| | - C Guillemet
- Medical Oncology Department, Centre Henri Becquerel, Rouen, France
| | - J-O Bay
- Medical Oncology Department, Centre Jean Perrin, Clermont Ferrand, France
| | - I Ray-Coquard
- Medical Oncology Department, Centre Léon Bérard and Claude Bernard University, Lyon, France
| | - L Haddag
- Department of Radiology, Gustave Roussy, Villejuif, France
| | - J Bonastre
- Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France
| | - R Kapso
- Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France
| | - A Fraslin
- Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France
| | - N Bouvet
- Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France
| | - O Mir
- Medical Oncology Department, Gustave Roussy, Villejuif, France
| | - S Foulon
- Department of Biostatistics and Epidemiology, Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France
| |
Collapse
|
5
|
Cerbone L, Combarel D, Geraud A, Foulon S, Costa Silva CA, Colomba-Blameble E, Derosa L, Guida A, Flippot R, Carril-Ajuria L, Mir O, Escudier B, Paci A, Albiges L. 727P Cabozantinib (Cabo) concentration (Cmin) association with toxicity (tox) and treatment failure in metastatic renal cell carcinoma (mRCC) patients: The MONICA study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
6
|
Foulon S, Cony-Makhoul P, Guerci-Bresler A, Delord M, Solary E, Monnereau A, Bonastre J, Tubert-Bitter P. Prévalence de la leucémie myéloïde chronique en 2014 en France à partir des données du Système national des données de santé. Rev Epidemiol Sante Publique 2019. [DOI: 10.1016/j.respe.2019.03.082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
7
|
Le Cesne A, Kapso Kapnang R, Foulon S, Bonastre J. Health-related quality of life in patients with advanced soft tissue sarcoma (ASTS): Results from the TSAR randomized phase III trial of the French Sarcoma Group. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy299.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Lapage L, Foulon S, Berti D, Poels P, Hoekman B, Vermeulen J, Ector J, Haemers P, Voros G, Garweg C, Willems R. 63Outsourcing telecardiology services: the possible decline in clinical workload could be lower than expected. Europace 2018. [DOI: 10.1093/europace/euy015.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | - S Foulon
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - D Berti
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - P Poels
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - B Hoekman
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - J Vermeulen
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - J Ector
- University of Leuven, Department of cardiovascular sciences, Leuven, Belgium
| | - P Haemers
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - G Voros
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - C Garweg
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - R Willems
- University of Leuven, Department of cardiovascular sciences, Leuven, Belgium
| |
Collapse
|
9
|
Lapage L, Foulon S, Berti D, Poels P, Hoekman B, Vermeulen J, Ector J, Haemers P, Voros G, Garweg C, Willems R. P1227A prospective analysis of the detailed workload of a telecardiology service. Europace 2018. [DOI: 10.1093/europace/euy015.708] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
| | - S Foulon
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - D Berti
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - P Poels
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - B Hoekman
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - J Vermeulen
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - J Ector
- University of Leuven, Department of cardiovascular sciences, Leuven, Belgium
| | - P Haemers
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - G Voros
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - C Garweg
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - R Willems
- University of Leuven, Department of cardiovascular sciences, Leuven, Belgium
| |
Collapse
|
10
|
Lapage L, Foulon S, Berti D, Poels P, Hoekman B, Vermeulen J, Ector J, Haemers P, Voros G, Garweg C, Willems R. 64Patient driven contacts: an unforseen burden for a telecardiology service. Europace 2018. [DOI: 10.1093/europace/euy015.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - S Foulon
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - D Berti
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - P Poels
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - B Hoekman
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - J Vermeulen
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - J Ector
- University of Leuven, Department of cardiovascular sciences, Leuven, Belgium
| | - P Haemers
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - G Voros
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - C Garweg
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - R Willems
- University of Leuven, Department of cardiovascular sciences, Leuven, Belgium
| |
Collapse
|
11
|
Lapage L, Foulon S, Berti D, Poels P, Hoekman B, Vermeulen J, Ector J, Haemers P, Voros G, Garweg C, Willems R. P423A retrospective analysis of the workload in a telecardiology service. Europace 2018. [DOI: 10.1093/europace/euy015.234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - S Foulon
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - D Berti
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - P Poels
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - B Hoekman
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - J Vermeulen
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - J Ector
- University of Leuven, Department of cardiovascular sciences, Leuven, Belgium
| | - P Haemers
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - G Voros
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - C Garweg
- University Hospitals (UZ) Leuven, Leuven, Belgium
| | - R Willems
- University of Leuven, Department of cardiovascular sciences, Leuven, Belgium
| |
Collapse
|
12
|
Blanchard P, Foulon S, Louvel G, Habibian M, Fizazi K. [A randomized controlled trial of metastases-directed treatment in patients with metastatic prostate cancer using stereotactic body irradiation: A GETUG-AFU trial]. Cancer Radiother 2017; 21:491-494. [PMID: 28869198 DOI: 10.1016/j.canrad.2017.06.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Accepted: 06/19/2017] [Indexed: 01/18/2023]
Abstract
The goal of treatment of metastatic prostate cancer remains palliation. The oligometastatic state could be the right time to intensify therapy by introducing metastases directed treatments. The aim of this trial was to evaluate the benefit of radiotherapy to all macroscopic metastatic sites and to the primary disease in patients with hormone sensitive oligometastatic prostate cancer.
Collapse
Affiliation(s)
- P Blanchard
- Département de radiothérapie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94800 Villejuif, France.
| | - S Foulon
- Service de biostatistiques, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - G Louvel
- Département de radiothérapie, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - M Habibian
- Groupe d'étude des tumeurs urogénitales, Unicancer, 101, rue de Tolbiac, 75654 Paris cedex 13, France
| | - K Fizazi
- Département de médecine oncologique, Gustave-Roussy Cancer Campus, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| |
Collapse
|
13
|
Garweg C, Vandenberk B, Voros G, Ector J, Foulon S, Willems R. P1772Leadless cardiac pacing system as first choice within patients with challenging conditions for conventional pacing. Europace 2017. [DOI: 10.1093/ehjci/eux161.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Mouaffak F, Foulon S, Smail F, Willoquet G. Clozapine : les dernières recommandations de la FDA et nous…. Encephale 2016; 42:600-601. [DOI: 10.1016/j.encep.2016.08.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Revised: 07/14/2016] [Accepted: 08/03/2016] [Indexed: 10/21/2022]
|
15
|
Lavaud P, Gravis G, Legoupil C, Foulon S, Joly F, Oudard S, Priou F, Soulié M, Mourey L, Latorzeff I, Delva R, Krakowski I, Laguerre B, Theodore C, Ferrero JM, Beuzeboc P, Habibian M, Boher J, Tergemina-Clain G, Fizazi K. How should we treat castration-resistant prostate cancer patients who have received androgen deprivation therapy (ADT) plus docetaxel upfront for hormone-sensitive diseae? Mature analysis of the GETUG-AFU 15 phase III trial. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw372.45] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
16
|
Foulon S, Weill A, Maura G, Dalichampt M, Debouverie M, Moreau T. Prévalence de la sclérose en plaques en France en 2012 et mortalité associée en 2013 à partir des données du Sniiram-PMSI. Rev Epidemiol Sante Publique 2015. [DOI: 10.1016/j.respe.2015.01.037] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
17
|
Foulon S, Farrington P, Benzenine E, Quantin C, Tubert-Bitter P, Escolano S. L’échantillon généraliste des bénéficiaires : un outil pour l’évaluation du risque vaccinal ? Rev Epidemiol Sante Publique 2014. [DOI: 10.1016/j.respe.2014.06.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
18
|
Gault N, Foulon S, Guillo S, Tubach F. Plans expérimentaux utilisés dans les études de pharmaco-épidémiologie menées sur bases de données de santé : une revue systématique. Rev Epidemiol Sante Publique 2014. [DOI: 10.1016/j.respe.2014.05.080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
19
|
Gaud N, Foulon S, Guillo S, Tubach F. Plans expérimentaux utilisés dans les études de pharmacoépidémiologie sur BDD de santé. Rev Epidemiol Sante Publique 2014. [DOI: 10.1016/j.respe.2013.12.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
20
|
Foulon S, Greacem T, Saïas T, Dugravier R, Guedeney A, Tubach F. Déterminants de l’attrition dans un essai randomisé d’intervention auprès de mères présentant des facteurs de vulnérabilité psychosociale : une étude ancillaire de l’essai CAPEDP. Rev Epidemiol Sante Publique 2014. [DOI: 10.1016/j.respe.2013.12.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
21
|
Dalloz M, Bottin L, Muresan I, Favrole P, Foulon S, Levy P, Drouet T, Marro B, Alamowitch S. Thrombolysis rate and impact of a stroke code: A French hospital experience and a systematic review. J Neurol Sci 2012; 314:120-5. [DOI: 10.1016/j.jns.2011.10.009] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2011] [Revised: 10/02/2011] [Accepted: 10/04/2011] [Indexed: 11/15/2022]
|
22
|
Ferrand H, Foulon S, Mangiapan G, Naccache JM, Taillé C, Bouaud J, Mayaud C, Cadranel J, Séroussi B, Lioté H. Validation des performances du logiciel Pneumodoc®pour l’aide au diagnostic d’imputabilité médicamenteuse des pneumopathies infiltrantes diffuses. Rev Mal Respir 2012. [DOI: 10.1016/j.rmr.2011.10.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
23
|
Lemmens D, Wouters M, Tempere J, Foulon S. Path integral approach to closed-form option pricing formulas with applications to stochastic volatility and interest rate models. Phys Rev E Stat Nonlin Soft Matter Phys 2008; 78:016101. [PMID: 18764014 DOI: 10.1103/physreve.78.016101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/26/2007] [Revised: 05/06/2008] [Indexed: 05/26/2023]
Abstract
We present a path integral method to derive closed-form solutions for option prices in a stochastic volatility model. The method is explained in detail for the pricing of a plain vanilla option. The flexibility of our approach is demonstrated by extending the realm of closed-form option price formulas to the case where both the volatility and interest rates are stochastic. This flexibility is promising for the treatment of exotic options. Our analytical formulas are tested with numerical Monte Carlo simulations.
Collapse
Affiliation(s)
- D Lemmens
- TFVS, Universiteit Antwerpen, Universiteitsplein 1, 2610 Antwerpen, Belgium
| | | | | | | |
Collapse
|
24
|
Heidbuchel H, van der Merwe N, Adams J, Foulon S, Goethals H, Willems R, Ector H. P-500 Comparative efficacy of bolus intravenous ATP and adenosine on sinus and AV nodal function. Europace 2003. [DOI: 10.1016/eupace/4.supplement_2.b184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022] Open
Affiliation(s)
- H. Heidbuchel
- University Hospital Gasthuisberg, University of Leuven
,
Leuven, Belgium
| | - N. van der Merwe
- University Hospital Gasthuisberg, University of Leuven
,
Leuven, Belgium
| | - J. Adams
- University Hospital Gasthuisberg, University of Leuven
,
Leuven, Belgium
| | - S. Foulon
- University Hospital Gasthuisberg, University of Leuven
,
Leuven, Belgium
| | - H. Goethals
- University Hospital Gasthuisberg, University of Leuven
,
Leuven, Belgium
| | - R. Willems
- University Hospital Gasthuisberg, University of Leuven
,
Leuven, Belgium
| | - H. Ector
- University Hospital Gasthuisberg, University of Leuven
,
Leuven, Belgium
| |
Collapse
|
25
|
Foulon S, Brosens F, Devreese JT, Lemmens LF. Density of a gas of spin-polarized fermions in a magnetic field. Phys Rev E Stat Nonlin Soft Matter Phys 2001; 63:016111. [PMID: 11304318 DOI: 10.1103/physreve.63.016111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/23/2000] [Indexed: 05/23/2023]
Abstract
For a fermion gas with equally spaced energy levels that is subjected to a magnetic field, the particle density is calculated. The derivation is based on the path integral approach for identical particles, in combination with the inversion techniques for the generating function of the static response functions. Explicit results are presented for the ground state density as a function of the magnetic field with a number of particles ranging from 1 to 45.
Collapse
Affiliation(s)
- S Foulon
- Departement Natuurkunde, Universiteit Antwerpen (UIA), Universiteitsplein 1, B-2610 Antwerpen, Belgium
| | | | | | | |
Collapse
|